부산대학교 도서관

In March 2009, the Scandiatransplant acceptable mismatch program (STAMP) was introduced as a strategy toward improving kidney allocation to highly sensitized patients. Patients with a transplantability score ≤ 2% are potential candidates for the program. Samples are analyzed and acceptable antigens (HLA‐A, B, C, DRB1, DRB3/4/5, DQB1, DQA1, DPB1, DPA1) are defined by the local tissue typing laboratory and finally evaluated by a steering committee. In the matching algorithm, patients have the highest priority when the donor's antigens are all among the recipient's own or acceptable HLA antigens. In the period from 2009 to 2020, we have transplanted 278 highly sensitized kidney patients through the program. The graft survival of the STAMP patients was compared with 9002 deceased donor kidney‐transplanted patients, transplanted in the same time period. The 10‐year graft survival was 73.4% (95% CI: 60.3–90.0) for STAMP and 82.9% (95% CI: 81.6–84.3) for the reference group. (p= .2). In conclusion, the 10‐year allograft survival demonstrates that the STAMP allocation algorithm is immunological safe. The program is continuously monitored and evaluated, and the introduction of matching for all HLA loci is a huge improvement to the program and demonstrate technical adaptability as well as clinical flexibility in a de‐centralized organization. The acceptable mismatch program administered by Scandiatransplant, the Nordic organ allocation organization, achieves 10‐year graft survival for highly sensitized patients that is comparable to non‐sensitized patients.